Innovator Resources

About-Us/Ebola_13.jpg

RA Capital works with biotech innovators, executives, and company-builders at all stages along the journey from idea to product. We're committed to sharing best practices and introducing new ways to address common challenges.

Join the Innovator Resources Mailing List:

Series I: Conducting a Logical, Data-Driven IPO


POSTED AUGUST 2021

What we call "Series I" IPO principles are increasingly recognized as common sense and in the best interest of any strong company going public. Review our roadmap for running a rigorous price discovery and allocation process and consider for yourself all the data supporting "Series I" logic over myth-based conventional IPOs.

LEARN MORE

Understanding the Value of Your Equity


POSTED MARCH 2020

If you are looking forward to a career in biotech, then you are an investor. Sound strange? Not at all--time is money, you are investing your time in a company, and they will pay you in both cash and equity. 10,000 shares of one company could be worth much more than 30,000 shares of another company, but to know when that’s true, you need to know what questions to ask.

LEARN MORE

Terms and Conditions

Back

Before accessing these resources, the reader must review and acknowledge the following terms and conditions

By clicking “I Agree”, you acknowledge the following terms and conditions.

Publications are provided for informational purposes only and do not constitute an offer to sell, a solicitation to buy, or a recommendation for any security, nor do they constitute an offer or endorsement of RA Capital Management ("RA Capital")'s investment advisory or other services by RA Capital. The content of the publications neither constitutes investment advice nor offers any opinion with respect to the suitability of any security. Accounts managed by RA Capital may invest in certain companies referenced in the publications; however, RA Capital makes no guarantees as to accuracy or completeness of views expressed in the publications. Views expressed in the publications are subject to change, and may have become unreliable for various reasons, including changes in market conditions or economic circumstances. Any disclosures as to RA Capital is subject to change and is only valid as of the date the statement was made. By accessing the publications, the reader agrees that he/she will not copy, reproduce, republish, upload, post, transmit, alter, or distribute the publications in any way that is inconsistent with the purposes for which they are offered, without the prior written consent of RA Capital.

 

This disclaimer is in addition to all disclaimers found on the RA Capital website.